Why the study?
Venous thromboembolism is a major cause of morbidity and mortality in cancer patients, making accurate risk assessment and intervention with newer preventive drugs vital.
Appropriate risk stratification and the use of newer agents like DOACs are vital for preventing VTE in high-risk cancer patients.
Answers are grounded in this paper and cite their sources.
May guide VTE prophylaxis decisions in cancer; leaves open need for updated RCTs on optimal DOAC use.
Venous thromboembolism (VTE) is a major cause of both morbidity and mortality in patients with cancer. Venous thromboembolism, which includes both deep vein thrombosis and pulmonary embolism, affects a sizable portion of patients with malignancy and can have potentially life threatening complications. Accurate assessment of risk as well as diagnosis and treatment of this process is paramount to preventing death in this high risk population. Various risk models predictive of venous thromboembolism in patients with cancer have been developed, and knowledge of these rubrics is essential for the treating oncologist. Subgroups of particular interest are inpatients receiving chemotherapy, postoperative patients after surgical debulking, and patients undergoing radiotherapy. Numerous newer drugs have become available for the prevention of venous thromboembolism in patients with cancer who are at high risk of developing the disease. These include the class of drugs called direct oral anticoagulants, (DOACs) which do not require the same monitoring that other modalities have previously required and are taken by mouth, preventing the discomfort associated with subcutaneous strategies. The appropriate risk stratification and intervention to prevent venous thromboembolism are vital to the treatment of patients with cancer.
No takes yet. Share an insight, caveat, or question.
Guntupalli et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: